Clinical studies continue to support the use of psilocybin for mental health. For example, a study from JAMA Psychiatry found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR. New York University. found “Psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression and led to decreased in cancer-related demoralization and hopelessness, improved spiritual well-being.” In addition, The Beckley Foundation said, “Psilocybin was well-tolerated and induced rapid and lasting reduction in the severity of depressive symptoms.” Helping, the US FDA says psilocybin is a “breakthrough therapy” for clinical depression. With more studies likely, it’s creating momentum for companies such as Numinus Wellness Inc. (TSXV:NUMI)(OTC:LKYSF), Cybin Inc. (NEO:CYBN)(OTC:CLXPF), Mind Medicine Inc. (NEO:MMED)(OTC:MMEDF), Compass Pathways (NASDAQ:CMPS), and Tryp Therapeutics Inc. (CSE:TRYP).
Numinus Wellness Inc. (TSXV:NUMI)(OTC:LKYSF) BREAKING NEWS: Numinus Wellness Inc.,
a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), is excited to announce it has acquired theOrbitrap Exploris 120 mass spectrometer with Vanquish Flex Binary instrument for its continued research and development of Psilocybe mushroom related projects at Numinus Bioscience, the Company's 7,000 square foot analytics and research laboratory.
Implementation of the Orbitrap, a state-of-the-art high resolution mass spectrometry instrument, will continue the accelerated trajectory of Numinus Bioscience’s research strategy to optimize cultivation, harvest, and extraction of Psilocybe mushrooms. This follows Numinus’ successful completion of the first legal extraction in Canada by a public company for research and development purposes in December.